(E)-(3,5-DIMETHYLISOXAZOL-4-YL)(2-((2,5-DIMETHYLPHENOXY)METHYL)PHENYL)METHANONE O-METHYL OXIME


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SGMZGGOXWYVRFB-ZNTNEXAZSA-N
Smiles	CO\N=C(/c1ccccc1COc2cc(C)ccc2C)\c3c(C)onc3C
InChI	InChI=1S/C22H24N2O3/c1-14-10-11-15(2)20(12-14)26-13-18-8-6-7-9-19(18)22(24-25-5)21-16(3)23-27-17(21)4/h6-12H,13H2,1-5H3/b24-22+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H24N2O3
Molecular Weight	364.44
AlogP	4.76
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	56.85
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity	Reference
Fungicidal activity against Blumeria graminis f. sp. tritici inoculated on wheat seedlings pre-treated with compound 24 hr before fungal inoculation assessed as inhibition of wheat powdery mildew disease at 500 ppm measured after 10 days under greenhouse conditions relative to untreated control	Blumeria graminis f. sp. tritici	90.0 %
Fungicidal activity against Podosphaera fuliginea inoculated on cucumber plants pre-treated with compound 24 hr before fungal inoculation assessed as inhibition of cucumber powdery mildew disease at 500 ppm measured after 10 days under greenhouse conditions relative to untreated control	Podosphaera fuliginea	90.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2288808
PubChem	76313026

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).